An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer

Stefano Cavalieri 1,2,*, Mara Serena Serafini 3, Andrea Carenzo 3, Silvana Canevari 4, Deborah Lenoci 3, Federico Pistore 1, Rosalba Miceli 5, Stefania Vecchio 6, Daniele Ferrari 7, Cecilia Moro 8, Andrea Spongini 9, Alessia Caldara 10, Maria Cossu Rocca 11, Simona Secondino 12, Gabriella Moretti 13, Nerina Denaro 14, Francesco Caponigro 15, Emanuela Vaccher 16, Gaetana Rinaldi 17, Francesco Ferraiu 18, Paolo Bossi 1, Lisa Licitra 1,2, and Loris De Cecco 5,8,*

Abstract: Epidermal growth factor receptor (EGFR) pathway has been shown to play a crucial role in several inflammatory conditions and host immune-inflammatory status is related to tumor prognosis. This study aims to evaluate the prognostic significance of a four-gene inflammatory signature in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients treated with the EGFR inhibitor cetuximab plus chemotherapy. The inflammatory signature was assessed on 123 R/M HNSCC patients, enrolled in the multicenter trial B490 receiving first-line cetuximab plus platinum-based chemotherapy. The primary endpoint of the study was progression free survival (PFS), while secondary endpoints were overall survival (OS) and objective response rate (ORR). The patient population was subdivided into 3 groups according to the signature score groups. The four-genes-signature proved a significant prognostic value, resulting in a median PFS of 9.2 months in patients with high vs. 6.2 months for intermediate vs. 3.9 months for low values of the score, respectively (\(p = 0.0016\)). The same findings were confirmed for OS, with median time of 18.4, 13.4, and 7.5 months for high, intermediate, and low values of the score, respectively (\(p = 0.0001\)). When ORR was considered, the signature was significantly higher in responders than in non-responders (\(p = 0.0092\)), reaching an area under the curve (AUC) of 0.65 (95% CI: 0.55–0.75). Our findings highlight the role of inflammation in the response to cetuximab and chemotherapy in R/M-HNSCC and may have translational implications for improving treatment selection.
Keywords: HNSCC; targeted therapy; cetuximab; gene-expression; immune biomarkers; inflammatory signature

1. Introduction

Recurrent head and neck squamous cell carcinoma (HNSCC) not amenable to loco-regional salvage therapies and metastatic HNSCC are treated with systemic approaches [1]. The treatment choice relies on patient- and disease-related factors, including patient’s performance status, comorbidities, disease-free interval, and previous therapies.

After the publication of the Keynote048 trial results [2], the state-of-the-art option for the so-called platinum-sensitive recurrent/metastatic (R/M) has changed. To date, according to international guidelines [1], patients with a combined positive score (CPS) ≥ 1 may receive pembrolizumab monotherapy or platinum-based chemotherapy and 5-fluorouracil (5-FU) plus immunotherapy with pembrolizumab. In contrast, subjects with a PD-L1-negative disease (CPS = 0), accounting for 15% of the R/M HNSCC patient population [2], are treated with platinum-based chemotherapy plus cetuximab. Among the available therapeutic options for PD-L1-negative R/M HNSCC, one of the available regimens is Extreme, which is made of the combination of cetuximab, cisplatin (or carboplatin for cisplatin-unfit subjects) and 5-fluorouracil (5-FU). In alternative regimens, 5-FU may be replaced by taxanes, either docetaxel or paclitaxel [1], or it might be omitted [3].

Monoclonal antibody-guided targeted therapy, such as anti-EGFR, and immune checkpoint inhibitors (ICI), alone or in combination with chemotherapy, have been approved for R/M HNSCC by FDA/EMA but, at variance to other types of tumors (i.e., colon cancer for cetuximab or lung and melanoma for ICIs), the percent of long-term responding patients is lower. To date, biomarkers to identify patients that could benefit from the therapy (predictive of therapy response and/or better overall survival) are still under investigation. Previously, we have shown that patients achieving long-lasting responses to the combination of chemotherapy and cetuximab showed a profile enriched in strong EGFR signaling phenotype and hypoxic differentiation [4].

Moreover, it is well-known that cetuximab plays a role in modulating the immune system in cancer [5–10]. As an example, proof of concept studies identified that inflammatory biomarkers can predict treatment response and favorable survival in patients who underwent first-line cetuximab plus chemotherapy in metastatic colorectal cancer [11,12]. However, while inflamed tumor microenvironment gene expression signatures are under evaluation as predictive biomarkers to ICI response in other type of cancers [13,14], at present, in the field of HNSCC, the relationship between inflammatory biomarkers, early treatment response, and cetuximab efficacy still needs to be elucidated.

With the present analysis, we aimed to explore the prognostic role of an inflammation signature in an R/M HNSCC patient population treated with a first-line cetuximab-based therapy in a multicenter phase II clinical trial [3].

2. Materials and Methods

2.1. Study Design and Case Material

Gene expression analysis was conducted on formalin-fixed paraffin-embedded (FFPE) primary tumor specimens of patients included in the multicenter B490 phase II randomized trial (Clinical trial number EudraCT# 2011-002564-24), in which patients received cetuximab plus cisplatin with/without paclitaxel (hereafter CetCis versus CetCisPac). For the present analysis, patients were selected for the availability of a primary tumor specimen, clinical information on response, and follow-up data. Detailed methods about eligibility criteria and treatments were described in the main paper of the clinical study [3]. The primary endpoint of the study was progression-free survival (PFS), defined as the time between the date of randomization and the date of progression or death without evidence of progression, whichever occurred first. Secondary endpoints were: (i) overall survival (OS),
defined as the interval between the date of randomization and that of death from any
case; (ii) objective response rate (ORR), according to Response Evaluation Criteria in Solid
Tumors (RECIST, Version 1.1). Follow-up data were updated in July 2020. This phase II
study was designed as a non-inferiority study between CetCis and CetCisPac, with PFS as a
primary endpoint. The non-inferiority was met and the final results showed no statistically
significant differences in terms of PFS, OS and best objective response rate. For these
reasons, we aggregated the data of the two arms for the analysis of PFS, OS, and the best
objective response. The study sponsor’s ethical committee approved the conduction of
the clinical trial on the 29 July 2011 (local study identifier INT35-11) and the translational
analyses on the 17 December 2013 (PG/U 0013329). All patients provided written informed
consent for translational research prior to study entry.

2.2. Gene Expression Analysis

The case material is based on primary tumors only collected at the first diagnosis and
archived as FFPE blocks. Since the specimens were retrieved for the translational research
purposes of the present study at the time of patient’s accrual in the trial, their storage was
in the range of 1–3 years. Being aware that FFPE processing and tissue storage could result
in highly degraded RNAs which might impair gene expression-based biomarker discovery
by RNAseq, we applied pre- and post-analytical quality checks to address these issues [15].
After histopathological revision by an expert pathologist, selected tumor areas from FFPE
blocks were manually macro-dissected and total RNA was immediately extracted. RNA
extraction was performed using the Qiagen RNeasy Mini Kit with the QIAcube robotic
station (Qiagen, Düsseldorf, Germany), according to the manufacturer’s recommendations.
Quantification and quality check were performed using the Qubit 3.0 fluorometer (Life
Technologies, Carlsbad, CA, USA) and the TapeStation 4200 system (Agilent Technologies,
Santa Clara, CA, USA). Transcriptome libraries were generated from 100 ngr of total RNA
with the TruSeq RNA Access Library Prep Kit (Illumina, San Diego CA, USA) following the
manufacturer’s instructions. Libraries were pooled (8 samples/pool), denatured, clustered
onto a high output sequencing flow cell (V2 chemistry), and sequenced on NextSeq500
(Illumina, San Diego CA, USA) in paired-end mode with a read length of 2 × 75 bp
generating 50 million reads/sample.

2.3. Bioinformatic Analysis

Raw reads were aligned to the human reference genome assembly GRCh38 through
the align () function of the Rsubread R package, version 2.0.1. A gapped index was built
for the reference genome through the Rsubread function buildindex. BAM files were
successively used as input to the featureCount function in order to obtain a raw count
matrix. Then, the variance stabilizing transformation (vst), in the DESeq2 R package was
applied to normalize the raw counts.

We assessed the value of a four-gene inflammatory signature, previously developed
based on literature data [16,17] and patented by Bristol Myers Squibb (Princeton, NJ,
USA) (patent numbers WO2020/198672 and WO2020/198676). The expression values of
the four-gene inflammatory signature, which included CD274, CD8A, LAG3, and STAT1,
were retrieved from the normalized data matrix. Following the signature data processing,
the gene expression values were scaled and combined to obtain a score. The signature
does not include any weight for the 4 genes that were simply scaled and combined; thus,
each gene contributed equally to the signature. The four-gene signature generates a
continuous score that is associated with the inflammation level assessed by the four genes
(i.e., high score -> high inflammation); the scores were stratified based on tertiles. Further
details about this inflammatory signature and its application to other types of cancer are
reported elsewhere [13,14].
2.4. Statistical Analysis

According to the groups of the gene signature scores, patients were stratified into three groups: high, intermediate, and low score. We estimated the signature stratification capability by the Kaplan–Meier method and compared the PFS and OS curves with log-rank test. Survival analysis and visualization were provided using survminer R package and ggSurvplot function. Uni- and multivariable Cox regression analyses were used to test the effect of the signature on PFS and OS by adjusting for ECOG (Eastern Cooperative Oncology Group) performance status (PS), an objective clinical scale to evaluating the overall clinical conditions of cancer patients assessing their activities of daily life and primary HNSCC site (oropharynx versus others) by using survminer and survival R packages. Results of the Cox analyses are reported in terms of hazard ratios (HR), corresponding 95% confidence intervals (95% CI) along with p-values at two-sided Wald test. ORR (CR or PR) was assessed using descriptive statistics, and the signature ability for discriminating responders from non-responders was measured by estimating the area under the receiver operating characteristic curve (ROC-AUC) using plotROC R package. All the statistical analyses were performed using R version 3.6.0. In all cases, statistical significance was set at 0.05.

3. Results

3.1. Patient Characteristics

A total of 201 patients were enrolled and 10 cases were excluded from the intention-to-treat analysis [3]. Out of the 191 randomized patients (100 CetCis arm; 91 CetCisPac arm), FFPE specimens of primary tumor were available and suitable for RNA extraction in 123 cases (64%), which were all included in survival analysis (PFS and OS) (Figure 1). Characteristics of patients with available RNA were consistent with the whole study population (Table 1) [3].

Figure 1. CONSORT diagram.
Table 1. Clinical-pathological characteristics of B490 study (n = 191) compared to the cohort considered in the current study with available RNA (n = 123) that was analyzed for gene expression.

| Variable                        | Study Population | Clinical Trial Article (n = 191) | Samples with Available RNA (n = 123) |
|---------------------------------|------------------|----------------------------------|-------------------------------------|
| Randomization arm               | Cetuximab + cisplatin | 100 (52%)                         | 61 (50%)                            |
|                                 | Cetuximab + cisplatin + paclitaxel | 91 (48%)                         | 62 (50%)                            |
| Age (years)                     | Median Range     | 63                               | 62                                  |
|                                 |                  | 33–83                            | 33–83                               |
| Sex, n (%)                      | Female/Male      | 42 (22%)/149 (78%)               | 27 (22%)/96 (78%)                   |
| ECOG PS, n (%)                  | 0/1              | 97 (51%)/94 (49%)                | 74 (60%)/49 (40%)                   |
| Primary tumor site, n (%)       | Oropharynx/Other | 70 (37%)/121 (63%)               | 49 (40%)/74 (60%)                   |
| HPV, n (%) (oropharynx only)    | Not tested/HPV-negative/HPV-positive | 41 (59%)/16 (23%)/13 (19%)     | 35 (71%)/6 (12%)/8 (16%)            |
| Site of recurrence, n (%)       | Missing/Local recurrence/Locoregional recurrence/Metastasis/Metastasis/local/regional recurrence/Regional recurrence | 3 (2%)/27 (14%)/42 (22%)/59 (31%)/49 (26%)/11 (6%) | 1 (1%)/14 (11%)/26 (21%)/37 (30%)/38 (31%)/7 (6%) |

3.2. Clinical Outcomes

After the survival data update in 2020, the median follow-up in the study cohort (123 patients) was 52.9 months (95% CI 26.7–74.9), and median PFS was 6.1 months (95% CI 4.9–7.2). PFS at landmark times 3, 6, 9, and 18 months were 76%, 51%, 32%, and 14%, respectively. Median OS was 12.4 months (95% CI 9.4–14.1). OS at 9, 12, and 18 months were 64%, 53%, and 36%, respectively. ORR was 45% and 61% in the CetCis and the CetCisPac arms, respectively (OR = 0.52; 95% CI: 0.24–1.1, p = 0.086 by Cochran–Mantel–Haenszel test). Apart from a longer median follow-up, these findings were consistent with the ones previously reported in the paper published in 2017 [3], and both primary and secondary endpoints confirm no difference between the two regimens.

3.3. Four-Gene Inflammatory Signature

Subdividing the patient population into three groups, according to the expression of the four-gene inflammatory signature, PFS was longer in patients with a higher inflammatory score than in those with lower score: median PFS 9.2 months (95% CI: 7.6–14.8) vs. 6.2 months (95% CI 5–8) vs. 3.9 months (95% CI: 3.2–5.5) in high, intermediate, and low score, respectively (p = 0.0016; Figure 2A). In the same three groups, median OS was 18.4 months (95% CI: 12.6–27.5) vs. 13.4 months (95% CI: 10.3–25.8) vs. 7.5 months (95% CI: 5.5–10.4), p = 0.0001 (Figure 2B).

The univariable Cox models including the four-gene inflammatory signature as a continuous variable (Table 2) showed that high inflammation is associated with improved PFS and OS; in addition, multivariable Cox models proved that the inflammatory score is a significant prognostic factor for both PFS and OS independently of ECOG PS and primary HNSCC site. When the signature is stratified in high, intermediate, and high scores (Supplementary Table S1), the univariable analyses by Cox models showed that patients belonging to the high score group and with the highest signature expression
experienced an improved PFS and OS compared with those in intermediate and low score groups and these results were confirmed at multivariable analyses by adjusting for ECOG PS (prognostic for PFS and OS) and primary HNSCC site (prognostic for OS only (Supplementary Table S1). This proves the prognostic value of the four-gene inflammatory signature in patients treated with cetuximab plus cisplatin-based chemotherapy.

**Figure 2.** Prognostic value of the inflammation signature. (A) Kaplan–Meier curves of B490 patients’ PFS associated to the four-gene inflammatory signature. (B) Kaplan–Meier curves of B490 patients’ OS associated to the four-gene inflammatory signature. Curve separation was assessed by the log-rank test. Samples were stratified based on tertiles: high (red), intermediate (yellow) and low (gray) inflammatory score groups.

ORR data were available in 112 cases (91%). The analyses were performed by comparing responders (subjects achieving either a complete or partial response, CR and PR respectively; n = 59) versus non-responders (subjects having either stable disease or disease progression as best response, SD and PD, respectively; n = 53). As a continuous variable, the studied inflammatory signature exhibited significantly higher values in responders than in non-responders (p = 0.0092; Figure 3A). The discriminative ability of the four-gene inflammatory signature reached a ROC AUC of 0.65 (95% CI: 0.55–0.75; Figure 3B).
Table 2. Univariate and multivariate cox proportional hazard regression analysis of the four-gene inflammatory signature (continuous variable), considering overall survival and progression free survival.

|                      | Overall Survival (OS) | Progression Free Survival (PFS) |
|----------------------|-----------------------|---------------------------------|
|                      | Univariable Analysis  | Multivariable Analysis          |
| HR (95% CI)          | p-Value               | HR (95% CI)                     | p-Value |
| inflammatory signature continuous variable | 0.66 (0.53–0.79) | 0.001 | 0.65 (0.51–0.82) | <0.001 |
| ECOG PS 1 vs. 0     | 1.28 (1.08–1.48)     | 0.213 | 1.51 (1.02–2.25) | 0.041 |
| subsite oropharynx vs. other | 1.52 (1.33–1.72) | 0.031 | 1.58 (1.07–2.34) | 0.022 |

Figure 3. The inflammatory score as continuous variable was associated to cetuximab response. (A) Boxplot of the inflammatory scores in responders (complete responders + partial responders, CR + PR) and non-responder (stable disease + progressive disease, SD + PD). The inflammatory score is based on scaled expression of the four genes retrieved from normalized RNAseq data, (B) receiver operating characteristics (ROC) curve and area under the curve (AUC) of the four-gene inflammatory signature.

4. Discussion

An inflamed phenotype seems important in predicting the response to cetuximab, whose activity is not limited to EGFR inhibition. Expression level and the copy number of EGFR failed to predict cetuximab response [18,19]. Cetuximab activity is known to be linked to its immune-modulating role, mediated mainly by antibody-dependent cel-
Cellular cytotoxicity (ADCC) [5]. In the present work, we demonstrated that a four-gene inflammatory signature has an independent prognostic role in forecasting PFS and OS in R/M HNSCC patients first-line treated with cetuximab plus platinum-based chemotherapy. This prognostic role was independent of clinical factors, such as PS and primary HNSCC site. Moreover, the gene signature was associated with an objective response.

Our findings are consistent with what was observed in other malignancies treated with ICI. The investigated four-gene inflammatory signature reflects key functions in immune modulation, such as interferon-γ/STAT1-dependent CD8+ T-cell expansion (STAT1 and CD8A genes), LAG-3–dependent T-cell exhaustion (LAG3 gene), and high PD-L1 (CD274 gene) expression. Previously, the signature was found to be associated with ORR and OS in a cohort of hepatocellular carcinoma patients treated with nivolumab [13]. An analogous prediction of the benefit from ICI was observed in advanced melanoma patients treated with nivolumab, ipilimumab, or their combination [20,21]. Furthermore, the signature was shown to be predictive of response in gastric/gastroesophageal junction cancer patients treated with nivolumab + /− ipilimumab [14].

Recent studies have shown that the PD-L1 expression assessed by immunohistochemistry is positively correlated with its gene expression [20,21], CD274 copy number changes [22], and amplification [23]. Therefore, for our analysis, we assumed that the CD274 component of the proposed gene expression signature could be used as a surrogate for PD-L1 expression. In the HNSCC setting, from one side, several studies showed that PD-L1 is a strong prognosticator, and that its expression is higher in radiosensitive tumors [24]. On the other hand, a meta-analysis revealed that PD-L1 expression detected by immunohistochemistry was not prognostic for HNSCC but turned out to predict PFS in R/M only [25]. In the Keynote048 clinical trial [2], PD-L1 expression was not a prognostic or a predictive factor in patients enrolled in the control arms treated with the Extreme regimen (cisplatin + 5-fluorouracil + cetuximab); thus, the prognostic role of PD-L1 in HNSCC is still under debate.

The involvement of CD8A gene in the proposed signature seems to confirm the well-known positive prognostic role of CD8+ tumor-infiltrating lymphocytes (TILs) in several cancers, including HNSCC [26]. In RAS wild-type colorectal cancer patients, cetuximab was shown to increase TILs together with PD-L1 and LAG3 upregulation [27]. We may hypothesize a similar mechanism in HNSCC as well, since RAS is very rarely mutated in this setting [28].

Another component of the studied gene signature is STAT1. In this context, the immune escape mediated by STAT1 inhibition and STAT3 activation can be a downstream pathway of EGFR [29]. Moreover, de-inhibition of STAT1 has been shown to be involved in HNSCC immune evasion. This hypothesis is supported by the fact that JAK2/STAT pathway, together with its interplay with IFN-γ, plays a strong role in both EGFR-mediated immune escape and PD-L1 upregulation [30]. Moreover, in preclinical models, the inhibition of EGFR has been shown to trigger STAT1 activation, thus enhancing the adaptive cellular immunity [31]. Therefore, the hypothesis that cetuximab activity could be related to immune-modulating activity is supported further.

In the R/M HNSCC setting, the clinical activity and the prolonged responses observed with the association of cetuximab and the anti-PD1 pembrolizumab seems to corroborate the validity of this hypothesis [32]. However, we have to admit a limitation in the current study which relied on the high percent of patients (around 40%) with no sufficient amount of tissue or poor quality of extracted RNA that precluded deeper molecular analyses. Since CPS is equal or higher than 1 in approximately 85% of R/M HNSCC patients [2], as per standard-of-care, the majority of subjects were treated in first line with pembrolizumab alone or chemo-immunotherapy [1]. However, the remaining 15% of cases were still treated with platinum-based chemotherapy plus cetuximab. For these patients, the results of this study will create a future direction and the opportunity to better decipher the biology of the disease, and the benefit of the systemic treatment. Our findings warrant the design of a dedicated prospective trial. In this setting, other gene expression signatures have demonstrated...
their role in predicting cetuximab activity in HNSCC, notably the Cl3-hypoxia group of six-cluster model proposed and validated by our group [4]. Differently from the four-gene inflammatory signature, this cluster is characterized by several onco-signatures, notably EGFR and RAS, and altered pathways, such as hypoxia over-expression, but not by immune system pathways. Therefore, it is possible that response to chemotherapy and cetuximab may be triggered by different pathways in HNSCC, with one component linked to EGFR trait and hypoxia and another one to inflammation and immune response. Further evaluations and a combination of the aforementioned signatures could potentially enable better forecasting of the response to cetuximab and immune-related treatments.

5. Conclusions

To our knowledge, the present work reported the first analysis of the four-gene inflammatory signature with respect to the clinical efficacy of cetuximab plus chemotherapy in HNSCC, suggesting its prognostic and predictive role in a newly analyzed clinical setting. We may anticipate that similar results might be observed in an HNSCC patient population treated with immunotherapy, alone or in combination with cetuximab. Further studies are needed to confirm this hypothesis.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells11193176/s1, Supplementary Table S1: Univariable and multivariable cox proportional hazard regression analysis of the four-gene inflammatory signature stratified based on scores.

Author Contributions: Conceptualization: L.D.C., L.L., and S.C. (Stefano Cavalieri); methodology: L.D.C., S.C. (Stefano Cavalieri), and R.M.; formal analysis: L.D.C., S.C. (Stefano Cavalieri), and A.C. (Andrea Carenzo); investigation: L.D.C., L.L., S.C. (Stefano Cavalieri), S.C. (Silvana Canevari), M.S.S., and D.L.; resources: S.C. (Silvana Canevari), L.D.C., and L.L.; data curation: S.C. (Stefano Cavalieri); writing—review and editing: L.D.C., S.C. (Stefano Cavalieri), S.C. (Silvana Canevari), L.L., M.S.S., D.L., R.M., and P.B.; visualization: L.D.C. and A.C. (Andrea Carenzo); patient recruitment and data provision: S.C. (Stefano Cavalieri), M.S.S., S.C. (Silvana Canevari), D.L., F.P., R.M., S.V., D.F., C.M., A.S., A.C. (Alessia Caldara), M.C.R., S.S., G.M., N.D., F.C., E.V., G.R., F.F., PB., L.L., and L.D.C.; funding acquisition: L.D.C., L.L., and S.C. (Silvana Canevari) All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by Bristol Myers Squibb (Princeton, NJ, USA) grant to Lisa Licitra (OT123-388), AIRC funding (IG 23573 Loris De Cecho and 14750 to Silvana Canevari) and FRRB (Fondazione Regionale per la Ricerca Biomedica) project Supporting Personalized Treatment Decisions in Head and Neck Cancer through Big Data-SuPerTreat, under the frame of EraPerMed JTC2019. The funders had no role in the design and conduct of the study.

Institutional Review Board Statement: The study sponsor’s ethical committee approved the conduct of the clinical trial on the 29 July 2011 (local study identifier INT35-11) and the translational analyses on the 17 December 2013 (PG/U 0013329).

Informed Consent Statement: All patients were enrolled in accordance with approved protocols, international standards of good clinical practice, institutional review board approvals, and institutional safety monitoring. Written informed consent was provided.

Data Availability Statement: The authors declare that the data are available upon reasonable request.

Acknowledgments: The authors are grateful to the patients, their families, investigators, co-investigators, and the study teams at each of the following participating sites: Gabriella Farina, Azienda Ospedaliera Fatebenefratelli e Ospedale Policlinico di Milano; Carmelo Iacono, Ospedale civile Maria Paternò Arezzo, Ragusa; Vincenzo Adamo, Azienda Ospedaliera Ospedali Riuniti Papardo Piacenza, Messina; Guido Carillo, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro; Ilaria Imarisio, IRCCS Policlinico San Matteo, Pavia; Giampaolo Tortora, Azienda Ospedaliera Universitaria Integrata di Verona—Policlinico G.B. Rossi, Verona; Silvia Spinazzè, Ospedale Regionale Valle d’Aosta Umberto Parini, Aosta; Carmelo Bengala, Ospedale della Misericordia—Azienda USL 9, Grosseto; Marco Ciaparrone, Ospedale San Giovanni Calibita—Fatebenefratelli—Isola Tiberina, Roma; Marco Merlini, Medical Oncology, St. Croce e Carle University Teaching Hospital and ARCO Foundation, Cuneo; Franco Nolé, Medical
Oncology, Istituto Europeo di Oncologia, Milan; Mario Airoldi, Medical Oncology 2, AOU Città della Salute and della Scienza, Turin; Laura Deborah Locati, Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Salvatore Lo Vullo, Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; Francesca Tettabianzi and Lital Hollander, Oncology, IRCCS Istituto di ricerche farmacologiche Mario Negri, Milan, Italy. The authors thank Silvana Pilotti for the histopathological revision.

**Conflicts of Interest:** Lisa Licitra declares the following conflict of interests. Grants/research supports (funds received by my institution for clinical studies and research activities in which I am involved): Astrazeneca, BMS, Boehringer Ingelheim, Celgene International, Debiopharm International SA, Eisai, Exelixis inc, Hoffmann-La Roche ltd, IRX Therapeutics inc, Medpace inc, Merck–Serono, MSD, Novartis, Pfizer, Roche. Honoraria or consultation fees (for public speaking/teaching in medical meetings and/or for expert opinion in advisory boards): Astrazeneca, Bayer, BMS, Eisai, MSD, Merck–Serono, Boehringer Ingelheim, Novartis, Roche, Debiopharm International SA, Sobi, Incyte Biosciences Italy srl, Doxa Pharma, Amgen, Nanobiotics Sa and GSK. Public speaking/teaching from research companies and commercial education providers: AccMed, Medical Science Foundation G. Lorenzini, Associazione Sinapsi, Think 2 IT, Atom Servizi, Prime Oncology, WMA Congress Education, Fasi, DueCi promotion Sr, M&I, Net Congress and Education, PRMA Consulting, Kura Oncology, Health and Life srl, Immuno-Oncology Hub. The remaining authors declare no conflict of interest.

**References**

1. Machiels, J.-P.; Leemans, C.R.; Golusinski, W.; Grau, C.; Licitra, L.; Gregoire, V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* 2020, 31, 1462–1475. [CrossRef] [PubMed]

2. Burtness, B.; Harrington, K.J.; Greil, R.; Soulières, D.; Tahara, M.; de Castro, G., Jr.; Psyrri, A.; Basté, N.; Neupane, P.; Brutland, A.; et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. *Lancet* 2019, 394, 1915–1928. [CrossRef]

3. Bossi, P.; Miceli, R.; Locati, L.; Ferrari, D.; Moretti, G.; Denaro, N.; Caponigro, F.; Airoldi, M.; Moro, C.; et al. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous squamous cell carcinoma of the head and neck. *Ann. Oncol.* 2017, 28, 2820–2826. [CrossRef] [PubMed]

4. Bossi, P.; Bergamini, C.; Siano, M.; Rocca, M.C.; Sponghini, A.P.; Favales, F.; Giannoccaro, M.; Marchesi, E.; Cortelazzi, B.; Perrone, F.; et al. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. *Clin. Cancer Res.* 2016, 22, 3961–3970. [CrossRef]

5. Monteverde, M.; Milano, G.; Strola, G.; Maffi, M.; Lattanzio, L.; Vivenza, D.; Tonissi, F.; Merlano, M.; Nigro, C.L. The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients. *Crit. Rev. Oncol. 2015*, 95, 179–190. [CrossRef]

6. Miyayuchi, S.; Kim, S.S.; Pang, J.; Gold, K.A.; Gutkind, J.S.; Califano, J.A.; Mell, L.K.; Cohen, E.E.; Sharabi, A.B. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. *Clin. Cancer Res.* 2019, 25, 4211–4223. [CrossRef]

7. Luedke, E.; Jaime-Ramirez, A.C.; Bhave, N.; Roda, J.; Choudhary, M.M.; Kumar, B.; Teknos, T.N.; Carson, W.E.; 3rd. Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell–activating cytokines. *Surgery 2012*, 152, 431–440. [CrossRef]

8. Srivastava, R.M.; Lee, S.C.; Filho, P.A.A.; Lord, C.A.; Jie, H.-B.; Davidson, H.C.; López-Albaitero, A.; Gibson, S.P.; Gooding, W.E.; Ferrone, S.; et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen–specific T-cell immunity in head and neck cancer patients. *Clin. Cancer Res.* 2013, 19, 1858–1872. [CrossRef]

9. Lattanzio, L.; Denaro, N.; Vivenza, D.; Varamo, C.; Strola, G.; Fortunato, M.; Chamorey, E.; Comino, A.; Monteverde, M.; Nigro, C.L.; et al. Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy. *Cancer Immunol. Immunother.* 2017, 66, 573–579. [CrossRef]

10. Baysal, H.; De Pauw, I.; Zaryouh, H.; De Waele, J.; Peeters, M.; Pauwels, P.; Vermorken, J.B.; Smits, E.; Lardon, F.; Jacobs, J.; et al. Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous carcinoma cell lines: Investigation of the role of cetuximab sensitivity and HPV status. *Br. J. Cancer 2020*, 123, 752–761. [CrossRef]

11. Jiang, J.; Ma, T.; Xi, W.; Yang, C.; Wu, J.; Zhou, C.; Wang, N.; Zhu, Z.; Zhang, J. Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy. *Cancer Manag. Res.* 2019, 11, 8657–8668. [CrossRef] [PubMed]

12. Yang, J.; Guo, X.; Wang, M.; Ma, X.; Ye, X.; Lin, P. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS. *Sci. Rep.* 2017, 7, 17166. [CrossRef] [PubMed]
13. Sangro, B.; Melero, I.; Wadhawan, S.; Finn, R.S.; Abou-Alfa, G.K.; Cheng, A.-L.; Yau, T.; Furuse, J.; Park, J.-W.; Boyd, Z.; et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. *J. Hepatol.* 2020, 73, 1460–1469. [CrossRef] [PubMed]

14. Lei, M.; Siemers, N.O.; Pandya, D.; Chang, H.; Sanchez, T.K.; Harbison, C.T.; Szabo, P.M.; Janjigian, Y.Y.; Ott, P.A.; Sharma, P.; et al. Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. *Clin. Cancer Res.* 2021, 27, 3926–3935. [CrossRef] [PubMed]

15. Califano, D.; Russo, D.; Scognamiglio, G.; Loso, N.S.; Spina, A.; Bello, A.M.; Capilungo, A.; Galdiero, F.; De Cecio, R.; Bevilacqua, S.; et al. Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. *Cells* 2020, 9, 903. [CrossRef] [PubMed]

16. Ayers, M.; Lunceford, J.; Nebozyn, M.; Murphy, E.; Loboda, A.; Kaufman, D.R.; Albright, A.; Cheng, J.D.; Kang, S.P.; Shankaran, V.; et al. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. *J. Clin. Invest.* 2017, 127, 2930–2940. [CrossRef] [PubMed]

17. Danaher, P.; Warren, S.; Lu, R.; Samayo, J.; Sullivan, A.; Pekker, I.; Wallden, B.; Marincola, F.M.; Cesano, A. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): Results from The Cancer Genome Atlas (TCGA). *J. Immunother. Cancer* 2018, 6, 63. [CrossRef]

18. Licitra, L.; Störkel, S.; Kerr, K.M.; Van Cutsem, E.; Pirker, R.; Hirsch, F.R.; Vermorken, J.B.; von Heydebreck, A.; Esser, R.; Celik, I.; et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies. *Eur. J. Cancer* 2013, 49, 1161–1168. [CrossRef]

19. Licitra, L.; Mesia, R.; Rivera, F.; Renenár, R.; Hitt, R.; Erfán, J.; Rottey, S.; Kawecki, A.; Zablotny, D.; Benasso, M.; et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. *Ann. Oncol.* 2011, 22, 1078–1087. [CrossRef]

20. Hodi, F.S.; Wolchok, J.D.; Schadendorf, D.; Larkin, J.; Qian, M.; Sacci, A.; Young, T.C.; Srivinasan, S.; Chang, H.; Wind-Rotolo, M.; et al. Abstract CT0357: Genomic analyses and immunotherapy in advanced melanoma. *Cancer Res.* 2019, 79, CT037. [CrossRef]

21. Karabajakian, A.; Bouaoud, J.; Michon, L.; Kamal, M.; Crozes, C.; Zrounba, P.; Auclair-Perossier, J.; Gadot, N.; Attignon, V.; Le Tourneur, C.; et al. Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. *Oral Oncol.* 2021, 119, 105368. [CrossRef] [PubMed]

22. Huang, R.S.; Murugesan, K.; Montesion, M.; Pavlick, D.C.; Mata, D.A.; Hiemenz, M.C.; Decker, B.; Frampton, G.; Albacker, L.A.; Ross, J.S. Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression. *J. Immunother. Cancer* 2021, 9, e002680. [CrossRef] [PubMed]

23. Gao, G.; Zhang, X.-D.; Qu, H.; Yao, B.; Zhou, Y.; Xiang, J.; Chen, C.; Hou, T.; Chen, K.; Xu, J. A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients. *Ann. Transl. Med.* 2021, 9, 677. [CrossRef] [PubMed]

24. Lv, X.; Qiao, Q.; Li, G. Prognostic Role of PD-1/PD-L1 Expression in Patients with Head And Neck Cancer and Its Correlation with HPV/p16. *Int. J. Radiat. Oncol.* 2018, 102, e333. [CrossRef]

25. Yang, W.-F.; Wong, M.C.; Thomson, P.; Li, K.-Y.; Su, Y.-X. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. *Cancer Cell* 2021, 36, 1078–1087. [CrossRef] [PubMed]

26. De Ruiter, E.J.; Ooft, M.L.; Devriese, L.A.; Willems, S.M. The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. *J. Immunother. Cancer* 2011, 6, e105368. [CrossRef] [PubMed]

27. Woolston, A.; Khan, K.; Spain, G.; Barber, I.J.; Griffiths, B.; Gonzalez-Exposito, R.; Hornsteiner, L.; Patil, Y.; Newey, A.; et al. Genomic and Transcriptranscriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. *Cancer Cell* 2019, 36, 35–50.e9. [CrossRef]

28. Ho, A.L.; Brana, I.; Haddad, R.; Bauman, J.; Bible, K.; Oosting, S.; Wong, D.J.; Ahn, M.-J.; Boni, V.; Even, C.; et al. Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. *J. Clin. Oncol.* 2021, 39, 1856–1864. [CrossRef]

29. Concha-Benavente, F.; Srivastava, F.; Ferrone, S.; Ferris, R.L. EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3. *OncoImmunology* 2013, 2, e27215. [CrossRef]

30. Ma, H.; Yang, W.; Zhang, L.; Liu, S.; Zhao, M.; Zhou, G.; Wang, L.; Jin, S.; Zhang, Z.; Hu, J. Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma. *Br. J. Cancer* 2019, 120, 317–330. [CrossRef]

31. Srivastava, R.M.; Trivedi, S.; Concha-Benavente, F.; Hyun-Bae, J.; Wang, L.; Seethala, R.R.; Iv, B.F.B.; Ferrone, S.; Ferris, R.L. STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. *Cancer Immunol. Res.* 2015, 3, 936–945. [CrossRef] [PubMed]

32. Sacco, A.G.; Chen, R.; Worden, F.P.; Wong, D.J.L.; Adkins, D.; Swiecicki, P.; Chai-Ho, W.; Oppelt, P.; Ghosh, D.; Bykowski, J.; et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: A random-label, multi-arm, non-randomised, multicentre, phase 2 trial. *Lancet Oncol.* 2021, 22, 883–892. [CrossRef]